BRIEF published on 10/21/2025 at 18:54, 10 months 26 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 10 months 26 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 11 months 10 days ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
BRIEF published on 10/06/2025 at 14:56, 11 months 10 days ago Threshold Crossing by Bpifrance at ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX Pharma
BRIEF published on 09/25/2025 at 20:21, 11 months 21 days ago ABIONYX Pharma: Financial results for the first half of 2025 Financial Results Research And Development Treasury France 2030 Plan ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 11 months 21 days ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
BRIEF published on 08/28/2025 at 18:56, 1 year ago ABIONYX Pharma 2025 half-year review Treasury Financial Support Turnover ABIONYX Pharma Semester 2025
PRESS RELEASE published on 08/28/2025 at 18:51, 1 year ago Inside Information / Other news releases ABIONYX Pharma provided an update on its activity and cash position for Q2 2025. Company's revenue, cash position, and government funding details revealed Revenue Cash Position Update Government Funding ABIONYX Pharma
BRIEF published on 08/27/2025 at 19:31, 1 year ago ABIONYX Pharma in talks for a strategic partnership in sepsis Strategic Partnership Innovative Therapies ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 08/27/2025 at 19:26, 1 year ago Inside Information / Other news releases ABIONYX Pharma initiates discussions with a major sepsis player for strategic partnership, aiming to accelerate CER-001 development. Relevance of innovative technology validated Strategic Partnership Innovative Technology ABIONYX Pharma Sepsis CER-001
Published on 09/17/2026 at 13:30, 16 minutes ago UniDoc Health Equips San Juan, Puerto Rico Ambulances With Live Patient Video
Published on 09/17/2026 at 13:30, 16 minutes ago Electric Royalties Reports Permitting Progress and New Exploration Results Across Critical Metals Royalty Portfolio
Published on 09/17/2026 at 13:00, 46 minutes ago Organto Foods Strengthens Scalable European Operating Platform and Launches AI Powered Operational Transformation
Published on 09/17/2026 at 13:00, 46 minutes ago Gold Terra Announces Fall Drilling with Three (3) Rigs Active on the Con Mine, Yellowknife, NWT
Published on 09/17/2026 at 13:00, 46 minutes ago NiobiumX Mining Inc. Appoints Athabasca Basin Discovery Geologist Erik Sehn to Board of Directors
Published on 09/17/2026 at 13:25, 20 minutes ago Custodian Property Income REIT plc: Results of Annual General Meeting
Published on 09/17/2026 at 13:25, 20 minutes ago CDTL Highlights E-Drive + EMB Technologies for Commercial Vehicles at IAA Transportation 2026
Published on 09/17/2026 at 13:25, 20 minutes ago ATOME PLC: Notice of Dispute and Intent to Submit Claim to Arbitration under the UK - Paraguay Bilateral Investment Treaty ("the Treaty" or "BIT")
Published on 09/17/2026 at 13:05, 40 minutes ago Aurzen Expands Its Presence in Germany with Launch on Joybuy, Bringing EAZZE D1 and ZIP to More Consumers
Published on 09/16/2026 at 17:45, 20 hours 1 minute ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 6 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 19 hours ago Report on the Combined General Meeting of the 10th of September 2026
